NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Forecast & News

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' Earnings History.

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Achillion Pharmaceuticals.

5 Wall Street analysts have issued 1-year target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $2.50 to $6.30. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $5.03 in the next twelve months. This suggests that the stock has a possible downside of 17.6%. View Analyst Price Targets for Achillion Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

Press coverage about ACHN stock has been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Achillion Pharmaceuticals.

Achillion Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 14,080,000 shares, an increase of 11.0% from the December 15th total of 12,680,000 shares. Based on an average trading volume of 3,130,000 shares, the short-interest ratio is presently 4.5 days. Approximately 10.3% of the company's stock are short sold. View Achillion Pharmaceuticals' Current Options Chain.

Some companies that are related to Achillion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Celldex Therapeutics (CLDX), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD) and Edap Tms (EDAP).

Achillion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Achillion Pharmaceuticals stock include David Scheer and Joseph Truitt. View Institutional Ownership Trends for Achillion Pharmaceuticals.

ACHN stock was bought by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Achillion Pharmaceuticals.

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACHN stock can currently be purchased for approximately $6.11.

Achillion Pharmaceuticals has a market capitalization of $855.69 million. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.View Additional Information About Achillion Pharmaceuticals.

The official website for Achillion Pharmaceuticals is http://www.achillion.com/.

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.